Mark Nathan Lampert

CeNeS Pharmaceuticals, Inc. discovers and develops proprietary pharmaceuticals to prevent and treat disorders and injuries of the nervous system. The company is headquartered in Cambridge, MA.

BVF, Inc. manages engages in investment business and manages biotech focused hedge funds. The firm manages Biotechnology Value Fund LP and Biotechnology Value Fund II LP. The company was founded by Mark Nathan Lampert on September 14, 1993 and is headquartered in San Francisco, CA.

BVF Partners LP (BVF) is a SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded in 1993 and is a subsidiary of BVF, Inc. BVF provides discretionary advisory services to private investment vehicles which includes commingled limited partnerships (the BVF Funds) and a limited liability entity organized for a single investor (Single Investor Fund) as well as to separately managed accounts.

Oppenheimer & Co., Inc. provides security brokerage services. It also offers investment banking and advice to high net worth investors, individuals, businesses and institutions. The company is headquartered in New York, NY.

Athersys, Inc. manufactures & markets pharmaceutical products and is engaged in the development and commercialization of therapeutic products to treat significant and life-threatening diseases. The company has three primary focus areas, which include: regenerative medicine (applying the MultiStem, cell therapy platform), medicinal chemistry & pharmacology genomics. It was founded in December 1995 and is headquartered at Cleveland, OH.

Biotica Technology Ltd. develops and manufactures pharmaceutical products. The company focuses on the discovery and development of novel therapeutics derived from polyketide through the targeted alteration of polyketide biosynthetic pathways. The firm was founded in 1996 by Peter Leadlay and Jim Staunton and is headquartered in Saffron Walden, GB.

Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA.

The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA.